Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
100%(9 trials)

Phase Distribution

Ph phase_1
7
78%
Ph phase_2
2
22%

Phase Distribution

7

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
7(77.8%)
Phase 2Efficacy & side effects
2(22.2%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(9)

Detailed Status

Completed9

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 17 (77.8%)
Phase 22 (22.2%)

Trials by Status

completed9100%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_1

Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)

NCT04506905
completedphase_1

A Study of Elpipodect (MK-8189) in Participants With Bipolar I Disorder (MK-8189-020)

NCT06273774
completedphase_1

Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)

NCT05227118
completedphase_2

Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)

NCT04624243
completedphase_1

A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)

NCT05893862
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04506905Phase 1

Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)

Completed
NCT06273774Phase 1

A Study of Elpipodect (MK-8189) in Participants With Bipolar I Disorder (MK-8189-020)

Completed
NCT05227118Phase 1

Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)

Completed
NCT04624243Phase 2

Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)

Completed
NCT05893862Phase 1

A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)

Completed
NCT02181803Phase 1

Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)

Completed
NCT03055338Phase 2

An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)

Completed
NCT04676425Phase 1

A Study to Investigate the Influence of Hepatic Impairment on Elpipodect (MK-8189) Treatment (MK-8189-012)

Completed
NCT05406440Phase 1

A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014)

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9